-
1
-
-
63249110872
-
Update in cystic fibrosis 2008
-
Ratjen F. Update in cystic fibrosis 2008. Am. J. Respir. Crit. Care Med. 179(6), 445-448 (2009).
-
(2009)
Am. J. Respir. Crit. Care Med.
, vol.179
, Issue.6
, pp. 445-448
-
-
Ratjen, F.1
-
2
-
-
70349815600
-
Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005
-
Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005. Chest 136(6), 1554-1560 (2009).
-
(2009)
Chest
, vol.136
, Issue.6
, pp. 1554-1560
-
-
Razvi, S.1
Quittell, L.2
Sewall, A.3
Quinton, H.4
Marshall, B.5
Saiman, L.6
-
3
-
-
32044445488
-
Microbiology of airway disease in a cohort of patients with cystic fibrosis
-
Lambiase A, Raia V, Del Pezzo M, Sepe A, Carnovale V, Rossano F. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect. Dis. 6, 4 (2006).
-
(2006)
BMC Infect. Dis.
, vol.6
, pp. 4
-
-
Lambiase, A.1
Raia, V.2
Del Pezzo, M.3
Sepe, A.4
Carnovale, V.5
Rossano, F.6
-
4
-
-
12844270608
-
Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis
-
Li Z, Kosorok MR, Farrell PM et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293(5), 581-588 (2005).
-
(2005)
JAMA
, vol.293
, Issue.5
, pp. 581-588
-
-
Li, Z.1
Kosorok, M.R.2
Farrell, P.M.3
-
5
-
-
0025355607
-
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa
-
Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr. 116(5), 714-719 (1990).
-
(1990)
J. Pediatr.
, vol.116
, Issue.5
, pp. 714-719
-
-
Kerem, E.1
Corey, M.2
Gold, R.3
Levison, H.4
-
6
-
-
70350446684
-
Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations
-
Flume PA, Mogayzel PJ, Robinson KA et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med. 180(9), 802-808 (2009).
-
(2009)
Am. J. Respir. Crit. Care Med.
, vol.180
, Issue.9
, pp. 802-808
-
-
Flume, P.A.1
Mogayzel, P.J.2
Robinson, K.A.3
-
7
-
-
39049142717
-
Exacerbations in cystic fibrosis: 3 - Management
-
Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3 - management. Thorax 63(2), 180-184 (2008).
-
(2008)
Thorax
, vol.63
, Issue.2
, pp. 180-184
-
-
Smyth, A.1
Elborn, J.S.2
-
8
-
-
0020573198
-
Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
-
Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr. Scand. 72(5), 651-657 (1983). (Pubitemid 13048784)
-
(1983)
Acta Paediatrica Scandinavica
, vol.72
, Issue.5
, pp. 651-657
-
-
Szaff, M.1
Hoiby, N.2
Flensborg, E.W.3
-
9
-
-
0034107646
-
Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs
-
Elborn JS, Prescott RJ, Stack BH et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 55(5), 355-358 (2000).
-
(2000)
Thorax
, vol.55
, Issue.5
, pp. 355-358
-
-
Elborn, J.S.1
Prescott, R.J.2
Stack, B.H.3
-
10
-
-
0002101312
-
Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; Observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol
-
di Sant Agnese PA, Anderson D. Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am. J. Dis. Child. 72, 17-61 (1946).
-
(1946)
Am. J. Dis. Child.
, vol.72
, pp. 17-61
-
-
Di Sant Agnese, P.A.1
Anderson, D.2
-
11
-
-
0034828531
-
Formulation of aerosolized therapeutics
-
Kuhn RJ. Formulation of aerosolized therapeutics. Chest 120(3 SUPPL.), 94S-98S (2001).
-
(2001)
Chest
, vol.120
, Issue.3 SUPPL.
-
-
Kuhn, R.J.1
-
12
-
-
0033531143
-
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group
-
Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1), 23-30 (1999).
-
(1999)
N. Engl. J. Med.
, vol.340
, Issue.1
, pp. 23-30
-
-
Ramsey, B.W.1
Pepe, M.S.2
Quan, J.M.3
-
13
-
-
50849131275
-
Shifting patterns of inhaled antibiotic use in cystic fibrosis
-
Moskowitz SM, Silva SJ, Mayer-Hamblett N et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr. Pulmonol. 43(9), 874-881 (2008).
-
(2008)
Pediatr. Pulmonol.
, vol.43
, Issue.9
, pp. 874-881
-
-
Moskowitz, S.M.1
Silva, S.J.2
Mayer-Hamblett, N.3
-
14
-
-
0034835277
-
Microbiological and immunologic considerations with aerosolized drug delivery
-
LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 120(3 SUPPL.), 118S-123S (2001).
-
(2001)
Chest
, vol.120
, Issue.3 SUPPL.
-
-
Lipuma, J.J.1
-
15
-
-
55549137086
-
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis
-
McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(9), 921-928 (2008).
-
(2008)
Am. J. Respir. Crit. Care Med.
, vol.178
, Issue.9
, pp. 921-928
-
-
McCoy, K.S.1
Quittner, A.L.2
Oermann, C.M.3
Gibson, R.L.4
Retsch-Bogart, G.Z.5
Montgomery, A.B.6
-
16
-
-
65949124667
-
Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis
-
Retsch-Bogart GZ, Quittner AL, Gibson RL et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 135(5), 1223-1232 (2009).
-
(2009)
Chest
, vol.135
, Issue.5
, pp. 1223-1232
-
-
Retsch-Bogart, G.Z.1
Quittner, A.L.2
Gibson, R.L.3
-
17
-
-
77950881382
-
-
Cystic Fibrosis Trust Cystic Fibrosis Trust, Kent, UK
-
Cystic Fibrosis Trust. UK CF Registry Annual Data Report 2008. Cystic Fibrosis Trust, Kent, UK (2009).
-
(2009)
UK CF Registry Annual Data Report 2008
-
-
-
18
-
-
60449117029
-
High treatment burden in adults with cystic fibrosis: Challenges to disease self- management
-
Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self- management. J. Cyst. Fibrosis 8(2), 91-96 (2009).
-
(2009)
J. Cyst. Fibrosis
, vol.8
, Issue.2
, pp. 91-96
-
-
Sawicki, G.S.1
Sellers, D.E.2
Robinson, W.M.3
-
20
-
-
0023607439
-
Selection and properties of Pseudomonas aeruginosa variants resistant to p-lactam antibiotics
-
Cullman W, Buscher KH, Dick W. Selection and properties of Pseudomonas aeruginosa variants resistant to p-lactam antibiotics. Eur. J. Clin. Microbiol. 6(4), 467-473 (1987).
-
(1987)
Eur. J. Clin. Microbiol.
, vol.6
, Issue.4
, pp. 467-473
-
-
Cullman, W.1
Buscher, K.H.2
Dick, W.3
-
21
-
-
27144521603
-
Simple method to determine p-lactam resistance phenotypes in Pseudomonas aeruginosa using the disc agar diffusion test
-
Vedel G. Simple method to determine p-lactam resistance phenotypes in Pseudomonas aeruginosa using the disc agar diffusion test. J. Antimicrob. Chemother. 56(4), 657-664 (2005).
-
(2005)
J. Antimicrob. Chemother.
, vol.56
, Issue.4
, pp. 657-664
-
-
Vedel, G.1
-
22
-
-
34948828022
-
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections
-
Hocquet D, Berthelot P, Roussel- Delvallez M et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob. Agents Chemother. 51(10), 3531-3536 (2007).
-
(2007)
Antimicrob. Agents Chemother.
, vol.51
, Issue.10
, pp. 3531-3536
-
-
Hocquet, D.1
Berthelot, P.2
Roussel-Delvallez, M.3
-
23
-
-
33646453620
-
Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates
-
Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50(5), 1633-1641 (2006).
-
(2006)
Antimicrob. Agents Chemother.
, vol.50
, Issue.5
, pp. 1633-1641
-
-
Quale, J.1
Bratu, S.2
Gupta, J.3
Landman, D.4
-
24
-
-
0032804038
-
Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
-
Shawar RM, MacLeod DL, Garber RL et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 43(12), 2877-2880 (1999).
-
(1999)
Antimicrob. Agents Chemother.
, vol.43
, Issue.12
, pp. 2877-2880
-
-
Shawar, R.M.1
MacLeod, D.L.2
Garber, R.L.3
-
25
-
-
0016611606
-
Cystic fibrosis: Comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride)
-
Dietzsch HJ, Gottschalk B, Heyne K, Leupoid W, Wunderlich P. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 55(1), 96-100 (1975).
-
(1975)
Pediatrics
, vol.55
, Issue.1
, pp. 96-100
-
-
Dietzsch, H.J.1
Gottschalk, B.2
Heyne, K.3
Leupoid, W.4
Wunderlich, P.5
-
26
-
-
77955040567
-
Reduced treatment time for colistinmethate sodium solutions (colistin CF) aerosolized by eFlow rapid, a novel electronic nebulizer
-
Presented at: Copenhagen, Denmark 15-18 June
-
Keller M, Hug M, Bietterle E, Bucholski A. Reduced treatment time for colistinmethate sodium solutions (colistin CF) aerosolized by eFlow rapid, a novel electronic nebulizer. Presented at: 29th European Cystic Fibrosis Conference. Copenhagen, Denmark, 15-18 June 2006.
-
(2006)
29th European Cystic Fibrosis Conference
-
-
Keller, M.1
Hug, M.2
Bietterle, E.3
Bucholski, A.4
-
28
-
-
33745686502
-
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
-
Gibson RL, Retsch-Bogart GZ, Oermann C et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol. 41(7), 656-665 (2006).
-
(2006)
Pediatr. Pulmonol.
, vol.41
, Issue.7
, pp. 656-665
-
-
Gibson, R.L.1
Retsch-Bogart, G.Z.2
Oermann, C.3
-
29
-
-
0022353251
-
Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
-
Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132(4), 761-765 (1985).
-
(1985)
Am. Rev. Respir. Dis.
, vol.132
, Issue.4
, pp. 761-765
-
-
Mendelman, P.M.1
Smith, A.L.2
Levy, J.3
Weber, A.4
Ramsey, B.5
Davis, R.L.6
-
30
-
-
0034771411
-
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis
-
Rosenfeld M, Gibson R, McNamara S et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J. Pediatr. 139(4), 572-577 (2001).
-
(2001)
J. Pediatr.
, vol.139
, Issue.4
, pp. 572-577
-
-
Rosenfeld, M.1
Gibson, R.2
McNamara, S.3
-
31
-
-
55549131738
-
In vitro performance of eFlow, an electronic inhaler for administration of a novel aztreonam formulation to CF patients
-
Bucholski A, Keller M, Balcke A et al. In vitro performance of eFlow, an electronic inhaler for administration of a novel aztreonam formulation to CF patients. Pediatr. Pulmonology S25(37), 321 (2003).
-
(2003)
Pediatr. Pulmonology
, vol.S25
, Issue.37
, pp. 321
-
-
Bucholski, A.1
Keller, M.2
Balcke, A.3
-
32
-
-
0020609861
-
Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction
-
Mihindu JC, Scheld WM, Bolton ND, Spyker DA, Swabb EA, Bolton WK. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob. Agents Chemother. 24(2), 252-261 (1983).
-
(1983)
Antimicrob. Agents Chemother.
, vol.24
, Issue.2
, pp. 252-261
-
-
Mihindu, J.C.1
Scheld, W.M.2
Bolton, N.D.3
Spyker, D.A.4
Swabb, E.A.5
Bolton, W.K.6
-
33
-
-
0021368586
-
Lack of cross-reactivity between aztreonam , a monobactam antibiotic, and penicillin in penicillin-allergic subjects
-
Saxon A, Hassner A, Swabb EA, Wheeler B, Adkinson NF Jr. Lack of cross-reactivity between aztreonam , a monobactam antibiotic, and penicillin in penicillin-allergic subjects. J. Infect. Dis. 149(1), 16-22 (1984).
-
(1984)
J. Infect. Dis.
, vol.149
, Issue.1
, pp. 16-22
-
-
Saxon, A.1
Hassner, A.2
Swabb, E.A.3
Wheeler, B.4
Adkinson Jr., N.F.5
-
34
-
-
0021910322
-
Investigation into the immunologic cross-reactivity of aztreonam with other p-lactam antibiotics
-
Saxon A, Swabb EA, Adkinson NF Jr. Investigation into the immunologic cross-reactivity of aztreonam with other p-lactam antibiotics. Am. J. Med. 78(2A), 19-26 (1985).
-
(1985)
Am. J. Med.
, vol.78
, Issue.2 A
, pp. 19-26
-
-
Saxon, A.1
Swabb, E.A.2
Adkinson Jr., N.F.3
-
35
-
-
0025861107
-
Safety of aztreonam in patients with cystic fibrosis and allergy to p-lactam antibiotics
-
Jensen T, Pedersen SS, Hoiby N, Koch C. Safety of aztreonam in patients with cystic fibrosis and allergy to p-lactam antibiotics. Rev. Infect. Dis. 13(SUPPL. 7), S594-S597 (1991).
-
(1991)
Rev. Infect. Dis.
, vol.13
, Issue.SUPPL. 7
-
-
Jensen, T.1
Pedersen, S.S.2
Hoiby, N.3
Koch, C.4
-
36
-
-
38349058630
-
A Phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
-
Retsch-Bogart GZ, Burns JL, Otto KL et al. A Phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Pulmonol. 43(1), 47-58 (2008).
-
(2008)
Pediatr. Pulmonol.
, vol.43
, Issue.1
, pp. 47-58
-
-
Retsch-Bogart, G.Z.1
Burns, J.L.2
Otto, K.L.3
-
37
-
-
73449119635
-
Effect of multiple courses of aztreonam lysine for inhalation (AZLI) on FEVt and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Analysis of 18 month data from CP-AI-006
-
Oermann CM, McCoy KS, Retsch- Bogart GZ, Gibson RL, Montgomery AB. Effect of multiple courses of aztreonam lysine for inhalation (AZLI) on FEVt and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): analysis of 18 month data from CP-AI-006. J. Cyst. Fibrosis 8 (SUPPL. 2), S28 (2009).
-
(2009)
J. Cyst. Fibrosis
, vol.8
, Issue.SUPPL. 2
-
-
Oermann, C.M.1
McCoy, K.S.2
Retsch- Bogart, G.Z.3
Gibson, R.L.4
Montgomery, A.B.5
-
38
-
-
77955034678
-
Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): Effect on disease related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA)
-
Oermann CM R-BG
-
Oermann CM R-BG, McCoy KS, Gibson RL, Quittner AL, Montgomery AB. Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): effect on disease related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA). Pediatr. Pulmonology 44(SUPPL. 32), 296 (2009).
-
(2009)
Pediatr. Pulmonology
, vol.44
, Issue.SUPPL. 32
, pp. 296
-
-
McCoy, K.S.1
Gibson, R.L.2
Quittner, A.L.3
Montgomery, A.B.4
-
39
-
-
27144479427
-
Development and validation of the Cystic Fibrosis Questionnaire in the United States: A health-related quality-of-life measure for cystic fibrosis
-
Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128(4), 2347-2354 (2005).
-
(2005)
Chest
, vol.128
, Issue.4
, pp. 2347-2354
-
-
Quittner, A.L.1
Buu, A.2
Messer, M.A.3
Modi, A.C.4
Watrous, M.5
-
40
-
-
66649116259
-
Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection
-
Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 135(6), 1610-1618 (2009).
-
(2009)
Chest
, vol.135
, Issue.6
, pp. 1610-1618
-
-
Quittner, A.L.1
Modi, A.C.2
Wainwright, C.3
Otto, K.4
Kirihara, J.5
Montgomery, A.B.6
-
41
-
-
65949085097
-
Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Interim analysis of 12 month data
-
Oermann CM, McCoy KS, Retsch- Bogart GZ, Gibson RL, Quittner AL, Montgomery AB. Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): interim analysis of 12 month data. J. Cyst. Fibrosis 7(S2), S25 (2008).
-
(2008)
J. Cyst. Fibrosis
, vol.7
-
-
Oermann, C.M.1
McCoy, K.S.2
Retsch- Bogart, G.Z.3
Gibson, R.L.4
Quittner, A.L.5
Montgomery, A.B.6
-
42
-
-
77952131777
-
Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens
-
Oermann CM, McCoy KS, Retsch- Bogart GZ, Gibson RL, McKevitt M. Montgomery AB. Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens. Pediatr. Pulmonol. 44(SUPPL. 32), S335 (2009).
-
(2009)
Pediatr. Pulmonol.
, vol.44
, Issue.SUPPL. 32
-
-
Oermann, C.M.1
McCoy, K.S.2
Retsch- Bogart, G.Z.3
Gibson, R.L.4
McKevitt, M.5
Montgomery, A.B.6
-
43
-
-
77952196413
-
Antibiotic susceptibility in Pseudomonas aeruginosa (PA) isolates following repeated exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis
-
Oermann CM, McCoy KS, Retsch- Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. Antibiotic susceptibility in Pseudomonas aeruginosa (PA) isolates following repeated exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis. Pediatr. Pulmonology 44(SUPPL. 32), 309 (2009).
-
(2009)
Pediatr. Pulmonology
, vol.44
, Issue.SUPPL. 32
, pp. 309
-
-
Oermann, C.M.1
McCoy, K.S.2
Retsch- Bogart, G.Z.3
Gibson, R.L.4
McKevitt, M.5
Montgomery, A.B.6
-
44
-
-
0036736583
-
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
-
Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 20(3), 658-664 (2002).
-
(2002)
Eur. Respir. J.
, vol.20
, Issue.3
, pp. 658-664
-
-
Hodson, M.E.1
Gallagher, C.G.2
Govan, J.R.3
-
45
-
-
34248358238
-
Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis
-
Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J. Cyst. Fibrosis 5(4), 261-263 (2006).
-
(2006)
J. Cyst. Fibrosis
, vol.5
, Issue.4
, pp. 261-263
-
-
Adeboyeku, D.1
Scott, S.2
Hodson, M.E.3
-
46
-
-
77952159044
-
Hospitalization risk of current standard of care (SOC) vs aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF)
-
Montgomery AB, Lewis S, Higuchi K, Marshall B, Oermann C. Hospitalization risk of current standard of care (SOC) vs aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF). Am. J. Respir. Crit. Care Med. 179, A1188 (2009).
-
(2009)
Am. J. Respir. Crit. Care Med.
, vol.179
-
-
Montgomery, A.B.1
Lewis, S.2
Higuchi, K.3
Marshall, B.4
Oermann, C.5
-
47
-
-
36248953255
-
Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health
-
Flume PA, O'Sullivan BP, Robinson KA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176(10), 957-969 (2007).
-
(2007)
Am. J. Respir. Crit. Care Med.
, vol.176
, Issue.10
, pp. 957-969
-
-
Flume, P.A.1
O'Sullivan, B.P.2
Robinson, K.A.3
-
48
-
-
69849098585
-
Effect of medication dosing frequency on adherence in chronic diseases
-
Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am. J. Manag. Care 15(6), e22-e33 (2009).
-
(2009)
Am. J. Manag. Care
, vol.15
, Issue.6
-
-
Saini, S.D.1
Schoenfeld, P.2
Kaulback, K.3
Dubinsky, M.C.4
-
49
-
-
31544472119
-
Pharmacokinetics of inhaled colistin in patients with cystic fibrosis
-
DOI 10.1093/jac/dki461
-
Ratjen F, Rietschel E, Kasel D et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57(2), 306-311 (2006). (Pubitemid 43160174)
-
(2006)
Journal of Antimicrobial Chemotherapy
, vol.57
, Issue.2
, pp. 306-311
-
-
Ratjen, F.1
Rietschel, E.2
Kasel, D.3
Schwiertz, R.4
Starke, K.5
Beier, H.6
Van Koningsbruggen, S.7
Grasemann, H.8
-
50
-
-
70349394321
-
Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients
-
Rottier BL, van Erp CJ, Sluyter TS, Heijerman HG, Frijlink HW, Boer AH. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J. Aerosol Med. Pulm. Drug Deliv. 22(3), 263-269 (2009).
-
(2009)
J. Aerosol Med. Pulm. Drug Deliv.
, vol.22
, Issue.3
, pp. 263-269
-
-
Rottier, B.L.1
Van Erp, C.J.2
Sluyter, T.S.3
Heijerman, H.G.4
Frijlink, H.W.5
Boer, A.H.6
-
51
-
-
73449119635
-
Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): Effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA)
-
Oermann CM, McCoy KS, Retsch- Bogart GZ . Gibson RL , Quittner A L , Montgomery AB. Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA). J. Cyst. Fibrosis 8(2 SUPPL.), S28 (2009).
-
(2009)
J. Cyst. Fibrosis
, vol.8
, Issue.2 SUPPL.
-
-
Oermann, C.M.1
McCoy, K.S.2
Retsch- Bogart, G.Z.3
Gibson, R.L.4
Quittner, A.L.5
Montgomery, A.B.6
-
52
-
-
34249945743
-
A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: A double-blind, placebo- controlled, multicenter study
-
Chuchalin A, Csiszer E, Gyurkovics K et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo- controlled, multicenter study. Paediatr. Drugs 9 (SUPPL. 1), 21-31 (2007).
-
(2007)
Paediatr. Drugs
, vol.9
, Issue.SUPPL. 1
, pp. 21-31
-
-
Chuchalin, A.1
Csiszer, E.2
Gyurkovics, K.3
-
53
-
-
70349123019
-
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa
-
Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(9), 3923-3928 (2009).
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, Issue.9
, pp. 3923-3928
-
-
Sabet, M.1
Miller, C.E.2
Nolan, T.G.3
Senekeo-Effenberger, K.4
Dudley, M.N.5
Griffith, D.C.6
-
54
-
-
54949136128
-
Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size
-
Li Z, Zhang Y, Wurtz W et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol. Med. Pulm. Drug Deliv. 21(3), 245-254 (2008).
-
(2008)
J. Aerosol. Med. Pulm. Drug Deliv.
, vol.21
, Issue.3
, pp. 245-254
-
-
Li, Z.1
Zhang, Y.2
Wurtz, W.3
-
55
-
-
70349084570
-
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection
-
Okusanya OO, Bhavnani SM, Hammel J et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother. 53(9), 3847-3854 (2009).
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, Issue.9
, pp. 3847-3854
-
-
Okusanya, O.O.1
Bhavnani, S.M.2
Hammel, J.3
-
56
-
-
34247193128
-
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
-
Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol. 42(4), 307-313 (2007).
-
(2007)
Pediatr. Pulmonol.
, vol.42
, Issue.4
, pp. 307-313
-
-
Geller, D.E.1
Konstan, M.W.2
Smith, J.3
Noonberg, S.B.4
Conrad, C.5
-
57
-
-
77955017576
-
Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder inhalation in adolescent patients with CF
-
Stass H, Nagelschmitz J, Posselt H. Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder inhalation in adolescent patients with CF. Pediatr. Pulmonol. 44(SUPPL. 32), 302 (2009).
-
(2009)
Pediatr. Pulmonol.
, vol.44
, Issue.SUPPL. 32
, pp. 302
-
-
Stass, H.1
Nagelschmitz, J.2
Posselt, H.3
-
58
-
-
34250899751
-
Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot study
-
Westerman EM, De Boer AH, Le Brun PP et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J. Cyst. Fibrosis 6(4), 284-292 (2007).
-
(2007)
J. Cyst. Fibrosis
, vol.6
, Issue.4
, pp. 284-292
-
-
Westerman, E.M.1
De Boer, A.H.2
Le Brun, P.P.3
-
59
-
-
70349444999
-
Antibacterial activities of a fosfomycin/ tobramycin combination: A novel inhaled antibiotic for bronchiectasis
-
MacLeod DL, Barker LM, Sutherland JL et al. Antibacterial activities of a fosfomycin/ tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J. Antimicrob. Chemother. 64(4), 829-836 (2009).
-
(2009)
J. Antimicrob. Chemother.
, vol.64
, Issue.4
, pp. 829-836
-
-
MacLeod, D.L.1
Barker, L.M.2
Sutherland, J.L.3
-
60
-
-
77950914953
-
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial
-
Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65(4), 286-291 (2009).
-
(2009)
Thorax
, vol.65
, Issue.4
, pp. 286-291
-
-
Ratjen, F.1
Munck, A.2
Kho, P.3
Angyalosi, G.4
-
61
-
-
67349204479
-
Early anti- pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study
-
Treggiari MM, Rosenfeld M, Mayer-Hamblett N et al. Early anti- pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp. Clin. Trials 30(3), 256-268 (2009).
-
(2009)
Contemp. Clin. Trials
, vol.30
, Issue.3
, pp. 256-268
-
-
Treggiari, M.M.1
Rosenfeld, M.2
Mayer-Hamblett, N.3
-
62
-
-
34147189596
-
Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis
-
Lebecque P, Leal T, Zylberberg K, Reychler G, Bossuyt X, Godding V. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J. Cyst. Fibrosis 5(4), 237-244 (2006).
-
(2006)
J. Cyst. Fibrosis
, vol.5
, Issue.4
, pp. 237-244
-
-
Lebecque, P.1
Leal, T.2
Zylberberg, K.3
Reychler, G.4
Bossuyt, X.5
Godding, V.6
-
63
-
-
0034546826
-
Technical report: Precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs
-
Prober CG, Walson PD, Jones J. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics 106(6), e89 (2000).
-
(2000)
Pediatrics
, vol.106
, Issue.6
-
-
Prober, C.G.1
Walson, P.D.2
Jones, J.3
-
64
-
-
34548048797
-
Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
-
Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 132(2), 562-568 (2007).
-
(2007)
Chest
, vol.132
, Issue.2
, pp. 562-568
-
-
Merlo, C.A.1
Boyle, M.P.2
Diener-West, M.3
Marshall, B.C.4
Goss, C.H.5
Lechtzin, N.6
-
65
-
-
70349761385
-
Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas: The EPIC study
-
Hamblett NM, Retsch-Bogart GZ, Treggiari M et al. Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas: the EPIC study. Pediatr. Pulmonology 44(SUPPL. 32), 183 (2009).
-
(2009)
Pediatr. Pulmonology
, vol.44
, Issue.SUPPL. 32
, pp. 183
-
-
Hamblett, N.M.1
Retsch-Bogart, G.Z.2
Treggiari, M.3
-
66
-
-
0021978780
-
Aztreonam: The first monobactam
-
Sykes RB, Bonner DP. Aztreonam: the first monobactam. Am. J. Med. 78(2 SUPPL. 1), 2-10 (1985).
-
(1985)
Am. J. Med.
, vol.78
, Issue.2 SUPPL. 1
, pp. 2-10
-
-
Sykes, R.B.1
Bonner, D.P.2
|